
2 May 2025
IntelliAM AI Plc
('IntelliAM' or the 'Company')
Board Appointment
IntelliAM AI plc (AQSE: INT), the software company leveraging the power of AI and machine learning in the manufacturing industry, announces the appointment of Dr Keith Harris to the board as non-executive director and Chairman-elect. Dr
Dr
He currently serves as Chairman of NASDAQ-listed gene therapy company MeiraGTx and Executive Chairman of Global Connectivity Plc, quoted on AQSE.
Strategic Appointment to Support Next Growth Phase
This appointment comes at a time of increasing momentum for IntelliAM, as the Company scales its AI-powered solutions across global industrial sectors. Dr
Tom Clayton, CEO of IntelliAM, commented:
"We are delighted to welcome Keith to the board. His extraordinary track record in capital markets and board leadership will bring enormous value to IntelliAM as we deepen our relationships with institutional investors and pursue our strategic growth initiatives."
Dr
"IntelliAM is delivering real transformation in a vital sector through the intelligent application of AI. I look forward to working with Tom and the board to support the company's ambitions and help realise its significant market potential."
Trading Update and Full-Year Results
The Company will publish a trading update for the year ended 31 March 2025 on 12 May 2025, followed by its audited full-year results in July 2025.
Disclosure of information required under Rule 4.9 of the Aquis Growth Market Access Rulebook
Keith Reginald Harris is, or has been in the last five years, a director of the following companies:
Current Directorships |
Former Directorships in the last five years |
MeiraGTx Holdings Plc |
Good Life Plus (previously Semper Fortis Esports Limited) |
Global Connectivity Plc |
Yesod Bio-Sciences Limited |
Keith Harris & Associates Limited |
Deneng Limited (previously As Sports Management Limited) |
Core Ldn Limited |
vTv Therapeutics Inc |
Voneus Limited |
|
Rural Broadband Solutions Holdings Limited |
|
TCRK Limited |
|
Cherwell Films LLP |
|
Dr
Dr
Dr
Dr
Except as set out above, there is no further information regarding Dr Harris that is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.
Our board of directors believes that Dr
Enquiries:
|
|
IntelliAM AI plc Tom Clayton, Chief Executive Officer Daud Khan, Chief Financial Officer
|
+44 114 299 5007 |
Oberon Capital - AQSE Corporate Adviser and Broker Adam Pollock Mike Seabrook Jessica Cave
|
+44 203 179 5300 |
Square1 Consulting - Financial PR David Bick |
+44 207 929 5599 +44 7831 381201 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.